Physical Activity Intervention for Individuals Newly Diagnosed With MS
NCT07731659
Autoimmune Diseases, Autoimmune Diseases of the Nervous System
Chicago, Illinois, United States
View Trial DetailsNCT Number: NCT07423312
1. To evaluate the effect of lead level on the pathogenesis of multiple sclerosis 2. Measure lead in blood sample of study groups 3. Estimate the expression level of DNA methyltransferase. 4. Evaluate oxidative stress markers, like MDA/8-OHdG 5. Measureδ-aminolevulinic acid 6. Correlate the clinical data of patients with biochemical markers
Trial opening soon.
Get Notified20 year–50 year
All sexes
Observational
inflammation, demyelination, gliosis, and neuronal loss are all components of multiple sclerosis (MS), a chronic autoimmune disease that affects the central nervous system (CNS). Myelinated axons in the CNS are the target of MS attacks, which can cause varying degrees of damage to both myelin and axons.MS affects 2.3 million people worldwide. MS is often diagnosed between the ages of 20 and 50 years, with females experiencing it more often than males. Four MS phenotypes exist: clinically isolated syndrome, relapsing-remitting (RRMS), secondary progressive and primary progressive.Many factors have been found to be associated, including environmental toxins..Pathological features that require explanation are the presence of demyelination in both white and grey matter , the targeting of oligodendrocytes, damage to the blood-brain barrier, inflammation in MS plaques and in the meninges, astrocyte activation, the central role of blood vessels and their perivascular spaces, and the presence of oxidative stress, mitochondrial damage, and oligodendrocyte apoptosis.Oxidative Stress and MS
.the oxidative damage of oligodendrocytes and neurons is associated with inflammation, and play a major role in neurodegeneration.Many autopsy studies describe an increase in various markers of lipid peroxidation, markers of DNA damage.CSF levels of trace metals involved in oxidative stress processes were the subject of a single study, which described increased lead, decreased magnesium, and similar calcium, manganese, and zinc levels in patients with primary progressive MS (PPMS) compared to those with secondary progressive MS (SPMS) and controls. lead(Pb) is a well-known toxic metal that threatens public health and is widely involved in the pathogenesis of MS. Accumulation of Pb in cells has been associated with the development of autoantibodies against different cellular structures such as neurofilaments, neuronal cytoskeletal proteins, and myelin basic protein.Lead exposure primarily occurs through ingesting tainted food or water, or inhaling Pb-contaminated air.The primary sources of occupational Pb exposure include the production of paint, recycling of batteries, wood preservation, welding, textile, printing, and handicraft industry . Some other sources, like canned food, cosmetics, lead pipes for water supply, and use of herbal products, also lead to Pb exposure in humans.The specific pathophysiological mechanisms mediating the relationship between environmental risk factors and MS susceptibility remain unknown, and DNA methylation may provide information on these mechanisms.This epigenetic pathway contributes to various MS pathophysiological processes, such as demyelination and remyelination, inflammatory response, and the collapse of the blood brain barrier (BBB).Research shows that lead has a deleterious impact on the immune system and is an important factor in inflammation. Lead also impacts cytokine metabolism (interleukins IL-1b, IL-4, IL-2, IL-8, and IL-6), TNF-α and INF-γ, and the expression of inflammatory enzymes (cyclooxygenases). Numerous studies have examined the impact of lead on immune system cells, including macrophages, B and T lymphocytes, and Langerhans cells. However, the impact depends on the kind of lead, dosage, route of entry, exposure period, age, host and genetic predisposition.Mechanisms by which lead may contribute to MS pathogenesis
Healthy volunteers accepted: Yes
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
Time frame: 2years
Time frame: 2years
Time frame: 2years
Time frame: 2years
Contact information is provided by the study sponsor or research team.
Assiut University
Other
Lead Exposure and Multiple Sclerosis;Biomarker Evidance and Clinical Impact.
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT07731659
Autoimmune Diseases, Autoimmune Diseases of the Nervous System
Chicago, Illinois, United States
View Trial DetailsNCT07723599
Autoimmune Diseases, Autoimmune Diseases of the Nervous System
Seattle, Washington, United States
View Trial DetailsNCT07706114
Autoimmune Diseases, Autoimmune Diseases of the Nervous System
San Francisco, California, United States
View Trial DetailsNCT07710742
Autoimmune Diseases, Autoimmune Diseases of the Nervous System
Bursa, Nilüfer, Turkey (Türkiye)
View Trial Details